Why the study?
Are circulating atrial natriuretic peptide levels elevated or deficient in patients with congestive heart failure and elevated cardiac filling pressures?
Are circulating atrial natriuretic peptide levels elevated or deficient in patients with congestive heart failure and elevated cardiac filling pressures?
This study establishes that atrial natriuretic peptide is elevated in congestive heart failure in response to increased cardiac filling pressures.
ANP elevation with high filling pressures in HF warrants cautious biomarker interpretation; leaves open whether ANP modulation affects outcomes.
A sensitive radioimmunoassay for atrial natriuretic peptide was used to examine the relation between circulating atrial natriuretic peptide and cardiac filling pressure in normal human subjects, in patients with cardiovascular disease and normal cardiac filling pressure, and in patients with cardiovascular disease and elevated cardiac filling pressure with and without congestive heart failure. The present studies establish a normal range for atrial natriuretic peptide in normal human subjects. These studies also establish that elevated cardiac filling pressure is associated with increased circulating concentrations of atrial natriuretic peptide and that congestive heart failure is not characterized by a deficiency in atrial natriuretic peptide, but with its elevation.
No takes yet. Share an insight, caveat, or question.
Burnett et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: